ABUNDANCE-&-HEALTH
Abundance & Health today announces positive results of a 4 week clinical trial investigating the anti-aging skin firming properties of their lead product Altrient® C, the world’s first liposomal vitamin C gel.
The results of the trial demonstrated that participants taking Altrient C had significantly improved their skin elasticity over the 4-week period of the clinical trial, compared to those taking the placebo. Participants using Altrient C had improved skin firmness and elasticity by 32.7% over the same period. After just 14 days, skin firmness and elasticity had already improved by 15.1% (over 1% a day on average). The trial tested the general skin firming properties of Altrient® C, rather than just those parts of the body that lotions are commonly applied to. 100% of participants reported that they would switch to Altrient C in favour of their current anti-aging skincare product.
“Skin elasticity is a critical part in the visual aging process, and thousands of years of research has so far provided limited results. This research has demonstrated a clear link between the skin aging process and vitamin C via dietary supplements,” said Jonathan Orchard, Director, Abundance & Health. “However, up to 85% of the vitamin C contained in tablets and powders is destroyed in the digestive system. Altrient C vitamin C is encased in a tiny bubble of protective fatty acids. This safeguards the vitamin through the harsh digestive system and the body’s absorption barriers, into the bloodstream, where it is transported through the body. This is a unique vitamin C delivery mechanism, ensuring maximum benefits. This research has shown that skin elasticity is considerably improved by this unique delivery system, ensuring that up to 98% of the vitamin C is absorbed straight into the bloodstream, reaching cells in the most effective way.”
The placebo-controlled trial was conducted by Aspen Clinical Research, the clinical and cosmetic industry researchers. The trial involved 60 participants with non-firm aging skin aged between 31 and 65+. 50% took 3 sachets of Altrient C a day for 4 weeks and 50% took a placebo. Participants’ skin firmness and elasticity were measured at three points throughout the trial by Cutometer MPA 580, the Courage + Khazaka electronic GmbH elasticity measurement device.
After 4 weeks, 100% of participants who consumed Altrient C reported an overall improvement in the skin. 50% noticed greater hydration. 43% thought they looked younger. 33% thought their skin appeared more nourished. 100% would change their current anti-aging routine by not just adding Altrient C to their skin regime, but replacing all products they currently use with Altrient C.
Abundance & Health plan to run a second clinical trial for a longer period, in order to measure a peak in the skins improvement. The second trial will determine how long improvements in skin elasticity will continue, as well as how much additional improvement can be measured.
“Skin ageing is a complex process involving genetic, hormonal and environmental factors,” said Dr Sanjay Rajpara, dermatologist and cosmetic skin doctor. “Formation of free oxygen radicals is widely accepted as a pivotal mechanism leading to skin ageing. The production of free radicals increases with ageing. Vitamin C is an important part of the body’s anti oxidative defence mechanism. Although there are some studies showing this benefit in vitro, there are not many showing direct effects of vitamin C in humans. This is a good quality study showing improvement in skin elasticity in human skin over a period of 4 weeks. This product has a potential to become one of the first line products for anti-ageing.”
“At Aspen Clinical Research, a leading expert in claim substantiation, we test thousands of products every year. We conducted a 4-week trial based upon industry standard techniques to assess the skin firming capabilities of an ingested dietary supplement, Altrient C,” said Danny McCamlie, Lead Clinical Scientist and Principal Investigator at Aspen Clinical. “We found that Altrient C caused an increase in skin firmness and skin elasticity under Cutometery assessments. With an increase of 15.1% and 32.7% in skin firmness, following 2 and 4 weeks respectively, Altrient C achieved results that, in our experience, some topically applied creams fail to achieve following 8 weeks of use.”
There were some results in addition to skin firmness. Of those taking Altrient C suffering from colds and flu, 36% recovered in 1-2 days, and 64% recovered in 3-4 days. This was in comparison to the placebo respondents where 82% took 5-6 days to recover. In addition, all of the subjects consuming Altrient C also reported a significant increase in their energy levels.
Additional Information
Vitamin C for anti-aging
Vitamin C is an extremely powerful antioxidant, playing a vital role in the production of collagen, the protein that gives skin its elasticity. As the aging process continues, collagen breaks down and wrinkles begin to appear, and skin eventually sags. If vitamin C levels are maintained, the body will always be able to produce the necessary levels of collagen, keeping fine lines and wrinkles at bay.
Altrient ® C: The New Generation of Vitamin C
Altrient® C’s unique delivery system ensures that up to 98% of the vitamin C is absorbed straight into the bloodstream, reaching the body’s cells in the most effective way. The product can be added to beverages, or taken directly with water.
Price: £29.95 for a box of 30 sachets
Stockist: www.abundanceandhealth.co.uk
-Ends-
Contact:
Image Box PR for Abundance & Health
Emma Marshall/Beth Warin
E:
emma@imageboxpr.co.uk
E: beth@imageboxpr.co.uk
T:
0208 943 4685
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
MultiBank Group Confirms $MBG Token Listings on MEXC and Gate.io on TGE Day in Addition to MultiBank.io and Uniswap18.7.2025 14:34:00 CEST | Press release
MultiBank Group, the world’s largest & most regulated financial derivatives institution, is proud to announce that its highly anticipated $MBG Token will be listed on two new major global cryptocurrency exchanges — MEXC and Gate.io — on the day of its official Token Generation Event (TGE), July 22, 2025, in addition to MultiBank.io and Uniswap. The $MBG Token will go live on: MultiBank.ioGate.ioMEXCUniswap This new dual listing will allow millions of users across both exchanges to seamlessly access and trade $MBG using their existing accounts, ensuring immediate market participation at launch. The Token Generation Event (TGE) is now approaching following the successful completion of two pre-sale rounds, where MultiBank Group issued 7 million tokens in Round 1 and 3 million tokens in Round 2 — both of which sold out within minutes. Naser Taher, Chairman and Founder of MultiBank Group said “With $MBG, we’re introducing a utility token built to deliver real-world value, transparency, and
SLB Announces Second-Quarter 2025 Results18.7.2025 12:50:00 CEST | Press release
Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially and decreased 4% year on year EPS, excluding charges and credits, of $0.74 increased 3% sequentially and decreased 13% year on year Net income attributable to SLB of $1.01 billion increased 27% sequentially and decreased 9% year on year Adjusted EBITDA of $2.05 billion increased 2% sequentially and decreased 10% year on year Cash flow from operations was $1.14 billion and free cash flow was $622 million Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the second-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716727689/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2025Mar. 31, 2025Jun. 30, 2024SequentialYear-on-yearReve
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum